Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661637 | 0.94 | MEN1 (0.56) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL339853 | 0.91 | MAOB (0.69) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL7349830 | 0.88 | CYP1A2 (0.58) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL5845963 | 0.87 | MAOB (0.64) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL7294232 | 0.87 | MAOB (0.50) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL4316231 | 0.87 | ALOX5 (0.49) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL27747848 | 0.87 | MAOB (0.64) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL4674930 | 0.86 | MEN1 (0.70) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL27406081 | 0.83 | AR (0.49) | MAOBALOX5MEN1KMT2ALMNA | |
| SCHEMBL8120621 | 0.82 | CYP4F2 (0.69) | MAOBALOX5MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | claimed |
| US-20180271808-A1 | METHODS OF REDUCING CHEMORESISTANCE AND TREATING CANCER | WAINER, IRVING W. | 2018-09-27 | — | — | US | disclosed |
| WO-2018140923-A1 | METHODS OF TREATING CANCER | MITCHELL WOODS PHARMACEUTICALS, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180042867-A1 | METHODS OF TREATING CANCER | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170172944-A1 | METHODS OF TREATING MELANOMA | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2017-06-22 | — | — | US | disclosed |
| CN-104478836-B | Benzofuran compounds and its preparation, purposes | 上海交通大学 | 2017-06-13 | — | — | CN | disclosed |
| EP-3125878-A2 | METHODS OF TREATING BREAST CANCER | Mitchell Woods Pharmaceuticals, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3125877-A2 | METHODS OF TREATING MELANOMA | Mitchell Woods Pharmaceuticals, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016144371-A1 | METHODS OF TREATING CANCER | MITCHELL WOODS PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| CN-105452244-A | Benzothiophene derivatives as estrogen receptor inhibitors | GLAXOSMITHKLINE IP DEV LTD | 2016-03-30 | — | — | CN | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5292759-A | O-benzyloxime ethers and crop protection agents containing these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-08 | — | — | US | disclosed |
| US-5194662-A | Insecticides, fungicides for plants | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271808-A1 | METHODS OF REDUCING CHEMORESISTANCE AND TREATING CANCER | GPR55, GPR68, GPR35 | MAOB 4219/4885ALOX5 357/4885MEN1 1945/4885 |
| US-20180042867-A1 | METHODS OF TREATING CANCER | GPR55, ADRB2, GRK2 | MAOB 1611/4885ALOX5 1325/4885MEN1 3028/4885 |
| US-20170172944-A1 | METHODS OF TREATING MELANOMA | CNR2, ADRB2, CNR1 | MAOB 737/4885ALOX5 1240/4885MEN1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.